[go: up one dir, main page]
More Web Proxy on the site http://driver.im/ Skip to main content
Springer Nature Link
Log in

High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Cyclins are a group of proteins that act as activators to cyclin-dependent kinases and are required for normal cell cycle transitions. Cyclin A is involved in the transitions between G1 to S and G2 to M. Its deregulation has been linked to a number of neoplasms, including endometrial cancer. The prognostic significance of cyclin A expression seems to be cancer-specific, and current knowledge on its impact on survival of endometrial cancer is limited. This study aimed to investigate the effect of cyclin A expression on cancer-specific survival and its correlation with conventional prognostic factors in endometrioid adenocarcinoma. Biopsies obtained from 211 patients were immunohistochemically stained for cyclin A and differences in expression analyzed at the Oulu University Hospital. Patients were divided into two groups utilizing the ROC curve. Further survival analyses were carried out between these two groups. In this study, we show that cyclin A expression correlates with tumor grade and FIGO stage. We also show that cyclin A is an independent prognostic factor in endometrioid adenocarcinoma. Whether cyclin A plays a role in tumorigenesis or merely is a marker of increased proliferation requires further studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
£29.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Finnish Cancer Registry. Cancer Statistics. 2011. http://www.cancer.fi/syoparekisteri/en/statistics/. Accessed: 30 Apr 2013.

  2. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynecol Obstet. 2009;105:109.

    Article  Google Scholar 

  3. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. Int J Gynecol Obstet. 2006;95:S105–43.

    Article  Google Scholar 

  4. Kyushima N, Watanabe J, Hata H, Jobo T, Kameya T, Kuramoto H. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol. 2002;128:307–12.

    Article  CAS  PubMed  Google Scholar 

  5. Arafa M, Somja J, Dehan P, Kridelka F, Goffin F, Boniver J, et al. Current concepts in the pathology and epigenetics of endometrial carcinoma. Pathology. 2010;42:613–7.

    Article  PubMed  Google Scholar 

  6. Ellis PE, Ghaem-Maghami S. Molecular characteristics and risk factors in endometrial cancer: what are the treatment and preventative strategies? Int J Gynecol Cancer. 2010;20:1207–16.

    Article  PubMed  Google Scholar 

  7. Honkavuori-Toivola M, Talvensaari-Mattila A, Soini Y, Turpeenniemi-Hujanen T, Santala M. Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma. Tumor Biol. 2012;33:935–41.

    Article  CAS  Google Scholar 

  8. Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumor Biol. 2013;34:571–6.

    Article  CAS  Google Scholar 

  9. Stamatakos M, Palla V, Karaiskos I, Xiromeritis K, Alexiou I, Pateras I, et al. Cell cyclins: triggering elements of cancer or not? World J Surg Oncol. 2010;8:111.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Yam CH, Funga TK, Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 2002;59:1317–26.

    Article  CAS  PubMed  Google Scholar 

  11. Yasmeen A, Berdel WE, Serve H, Muller-Tidow C. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2003;3:617–33.

    Article  CAS  PubMed  Google Scholar 

  12. Kayaselcuk F, Erkanli S, Bolat F, Seydaoglu G, Kuscu E, Demirhan B. Expression of cyclin H in normal and cancerous endometrium, its correlation with other cyclins, and association with clinicopathologic parameters. Int J Gynecol Cancer. 2006;16:402–8.

    Article  CAS  PubMed  Google Scholar 

  13. Horree N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP. Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J Clin Pathol. 2008;61:36–42.

    Article  CAS  PubMed  Google Scholar 

  14. Gallorini M, Cataldi A, di Giacomo V. Cyclin-dependent kinase modulators and cancer therapy. BioDrugs. 2012;26:377–91.

    CAS  PubMed  Google Scholar 

  15. Wesierska-Gadek J, Maurer M, Zulehner N, Komina O. Whether to target single or multiple CDKs for therapy? That is the question. J Cell Physiol. 2011;226:341–9.

    Article  CAS  PubMed  Google Scholar 

  16. Kallakury BV, Ambros RA, Hayner-Buchan AM, Sheehan CE, Malfetano JH, Ross JS. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes. Int J Gynecol Pathol. 1998;17:320–6.

    Article  CAS  PubMed  Google Scholar 

  17. Shih HC, Shiozawa T, Kato K, Imai T, Miyamoto T, Uchikawa J, et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol. 2003;34:471–8.

    Article  CAS  PubMed  Google Scholar 

  18. Watanabe J, Nishimura Y, Tsunoda S, Kawaguchi M, Okayasu I, Kuramoto H. Liquid-based preparation for endometrial cytology—usefulness for predicting the prognosis of endometrial carcinoma preoperatively. Cancer. 2009;117:254–63.

    PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Oulu University Hospital, P.O. Box 24, 90029, Oulu, Finland

    Simi Santala, Anne Talvensaari-Mattila, Maria Honkavuori-Toivola & Markku Santala

  2. Department of Pathology, Oulu University Hospital, P.O. Box 24, 90029, Oulu, Finland

    Ylermi Soini

  3. Department of Pathology and Forensic Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, School of Medicine, Cancer Center of Eastern Finland, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland

    Ylermi Soini

Authors
  1. Simi Santala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Talvensaari-Mattila
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ylermi Soini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Honkavuori-Toivola
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Markku Santala
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markku Santala.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Santala, S., Talvensaari-Mattila, A., Soini, Y. et al. High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma. Tumor Biol. 35, 5395–5399 (2014). https://doi.org/10.1007/s13277-014-1703-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1703-9

Keywords

Search

Navigation